DEA Wants More Psychedelics for Research Purposes - Ganjapreneur | Where to buy Skittles Moonrock online

Learn where to buy marijuana online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

DEA Wants to Increase Psychedelics in Research Purposes – Ganjapreneur (19459000)

Mon / Sep 30th

By: Graham Abbott

The DEA proposes revised 2024 and 2025 production quotas of research-grade psychedelics, including psilocybin, psilocin, and ibogaine. The agency claims that the new production rates will help to stimulate new research.

The full story is below the jump.

According to a report, the Drug Enforcement Administration (DEA), last week, proposed an increase in its 2024 production quotas of research-grade psychedelics including psilocybin and psilocin. Lucid News report.

The revised production schedule has been posted In a notice Federal Reserve calls for an increase in production from 20,000 grams to 30,000 grams of Psilocybin, and from 24,000 grams to 36,000 grams psilocin. This is a 50% increase. These numbers represent the DEA’s production quotas of these substances for 2025.

The report stated that the agency also recommended increasing the production of MDMA and DMT in 2025, but did not recommend increasing the production.

The agency said that the increased production rate is necessary to drive and fund new research into the effects of psychedelic drugs, many of which fall under Schedule I of federal law.

These increases are intended to support the research and clinical trials of DEA-registered Schedule I researchers. These proposed increases show DEA’s commitment to research on schedule I controlled substances. The proposed increases reflect the need for research and development as part of the FDA approval process of new drug products.” — Excerpt taken from the DEA Notice

Previous DEA The company has announced a massive increase in its production rates of psychedelics In 2022 In preparation for an important research push. The agency has also suggested reducing the production rates for fentanyl (for sales), hydrocodone, hydromorphone, oxycodone, and hydromorphone (for sales) next year.

The FDA has recently designated both psilocybin (also known as MDMA) and MDMA as “breakthrough therapies” — although it later retracted this designation. highlighted concerns About the initial investigations into MDMA’s potential as a treatment for post-traumatic disorder (PTSD).

Get daily cannabis industry news updates. Subscribe to our Newsletter

Do you have a different perspective to share with us? Send us a message Let us knowIf our editors choose your comment, it could be featured on this page.